Bronchial asthma
Conditions
Interventions
Control group 1:Zhichuan ling oral liquid and Samet troticasone powder inhaler
Control group 2:Samet troticasone powder inhaler
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of bronchial asthma; 2. The severity of the disease is mild to moderate persistent (i.e. grade 2-3), and the asthma is not well controlled; 3. Patients with asthma control test (ACT) score < 20; 4. Patients aged 18-65; 5. Patients willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with upper and lower respiratory tract infection, tuberculosis, pulmonary interstitial fibrosis, thoracic deformity, chronic obstructive pulmonary disease, bronchiectasis, cystic pulmonary fibrosis, allergic bronchopulmonary aspergillosis, allergic granulomatous vasculitis and other infectious, restrictive pulmonary diseases and other air flow obstructive pulmonary diseases that may affect the efficacy evaluation; 2. For patients with seasonal asthma, the treatment period <= 2 months per year according to symptoms of asthma and other special types of asthma; 3. Current smokers or patients who have quit smoking for less than 6 months; 4. Patients with other serious heart, brain, liver, kidney, immune system, blood system and other diseases, in which ALT and AST are 1.5 times higher than the upper limit of normal value, Cr is higher than the upper limit of normal value; 5. Patients who are known to be allergic to the components of the test drug and allergic constitution; 6. patients with hypertension, coronary heart disease, hypertrophy of prostate, urinary retention, arrhythmia and glaucoma. 7. Patients with asthma and asthma in attack stage, and patients with deficiency asthma in chronic persistent stage; 8. Pregnant, lactating and childbearing women who do not use contraceptive plans; 9. Patients suspected of or having a history of alcohol or drug abuse, or suffering from mental illness; 10. Patients who have participated in or are participating in other clinical trials within 3 months before screening; 11. Patients who are not suitable for the clinical trial in the opinion of researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Asthma control test;Asthma Related Quality of Life Questionnaire;fractional exhaled nitric oxide (FeNO);peak expiratory flow (PEF);rate of exacerbations; | — |
Countries
China
Contacts
Public ContactJiangtao Lin
China-Japan Friendship Hospital
Outcome results
None listed